肺免疫预后指数在广泛期小细胞肺癌中的验证:CASPIAN与IMpower133三期试验事后分析
本研究利用CASPIAN和IMpower133两项III期试验数据,在1140例广泛期小细胞肺癌患者中验证肺免疫预后指数(LIPI)的预后价值。LIPI良好、中间、不良组的中位OS分别为14.6、10.9、8.4个月(p<0.0001),多因素分析显示LIPI是OS和PFS的独立预后因素。LIPI不良患者从免疫治疗中获益有限,但未观察到显著的治疗-LIPI交互作用。
要点
- LIPI良好、中间、不良组的中位OS分别为14.6、10.9、8.4个月。
- LIPI是不良OS(HR 1.76)和PFS(HR 1.59)的独立预后因素。
- LIPI不良患者从免疫治疗中获益有限,但无显著治疗交互作用。
核心结论
- LIPI在广泛期小细胞肺癌中是稳健且临床可用的预后生物标志物。
- LIPI不良患者结局显著更差且从免疫治疗中获益有限,需新型治疗策略。
研究设计与样本
- CASPIAN和IMpower133两项III期试验的事后分析,共纳入1140例广泛期小细胞肺癌患者。
- LIPI分组:良好(dNLR<3且LDH<ULN)、中间(dNLR≥3或LDH≥ULN)、不良(dNLR≥3且LDH≥ULN)。
主要发现
- LIPI良好占34%,中间占49%,不良占17%;708例接受化疗-免疫治疗,432例接受单纯化疗。
- LIPI不良与较低白蛋白水平和较高肝转移率相关。
- 中位OS:良好14.6个月(95%CI 12.4-15.9),中间10.9个月(10.1-11.5),不良8.4个月(7.1-9.3),p<0.0001。
- 多因素分析中LIPI是OS独立预后因素(不良vs良好HR 1.76,95%CI 1.45-2.15,p<0.001)和PFS独立预后因素(HR 1.59,95%CI 1.33-1.90,p<0.001)。
关键数值与推荐
- LIPI良好:dNLR<3且LDH<ULN;中间:dNLR≥3或LDH≥ULN;不良:dNLR≥3且LDH≥ULN。
临床怎么用
- LIPI可用于广泛期小细胞肺癌患者治疗前的预后分层,辅助临床决策。
- 对LIPI不良患者应关注其免疫治疗获益有限,考虑探索新型治疗策略。
局限性
- 为事后分析,非预设验证性分析。
- 未观察到显著的治疗-LIPI交互作用,免疫治疗获益有限为描述性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Lung Immune Prognostic Index (LIPI) is an inflammation-based biomarker associated with outcomes to immunotherapy across several tumor types. Its prognostic value in extensive-stage small-cell lung cancer (ES-SCLC), however, remains insufficiently validated. We aimed to validate the prognostic impact of LIPI in ES-SCLC using data from two phase III trials. METHODS: Patients enrolled in the CASPIAN (NCT03043872) and IMpower133 (NCT02763579) trials were included. LIPI groups were defined as good (dNLR<3 and LDH<ULN), intermediate (dNLR≥3 or LDH≥ULN) and poor (dNLR≥3 and LDH≥ULN). Overall survival (OS) and progression-free survival (PFS) were assessed across LIPI categories and treatment arms. RESULTS: LIPI was available for 1140 patients (Good: 34%, Intermediate: 49%, Poor: 17%), including 708 treated with chemotherapy-immunotherapy and 432 with chemotherapy alone. Poor LIPI was associated with unfavorable characteristics, including lower albumin levels and higher rate of liver metastases. Median OS was 14.6 months (95%CI: 12.4-15.9) for LIPI Good, 10.9 (10.1-11.5) for Intermediate, and 8.4 (7.1-9.3) for Poor (p < 0.0001). In multivariate models adjusted on gender, age, ECOG, treatment arm and metastatic sites, LIPI remained an independent prognostic factor for OS (HR Poor vs. Good: 1.76, 95%CI: 1.45-2.15, p < 0.001) and PFS (HR: 1.59, 95%CI: 1.33-1.90, p < 0.001). Although patients with poor LIPI derived limited benefit from immunotherapy, no significant treatment-LIPI interaction was observed. CONCLUSION: This large post hoc analysis confirms LIPI as a robust and clinically applicable prognostic biomarker in ES-SCLC. Patients with poor LIPI have substantially worse outcomes and limited benefit from immunotherapy, highlighting the need for novel therapeutic strategies in this subgroup.
引用
- Auclin E, Roulleaux Dugage M, Gorría T, et al. Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials. Eur J Cancer. 2026. PMID: 42520592. doi:10.1016/j.ejca.2026.116955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。